Key facts
- Developer of novel therapeutics designed to address autoimmune diseases and improve patient outcomes.
- It has raised $850K across 1 recorded rounds; the latest was Seed Round ($2.7M) in Feb 2025.
- Maxymune Therapeutics has filed 1 Form D with the SEC, most recently Feb 2025 ($850K sold to 8 investors).
- Status: Privately Held (backing).
Free account
More of Maxymune Therapeutics with a free account
- ·Watch Maxymune Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required
Funding rounds
1 roundsAbout Maxymune Therapeutics
Developer of novel therapeutics designed to address autoimmune diseases and improve patient outcomes. The company's platform focuses on creating innovative molecules targeting new pathways and enhancing formulations of existing treatments, enabling healthcare professionals for better disease management for patients with autoimmune conditions, while improving adherence and reducing side effects for a more effective treatment experience.
- Sector
- Healthcare
- HQ
- Los Altos, CA, United States
- Founded
- 2022
- Website
- maxymunetx.com/
- Ownership
- Privately Held (backing)
Valuation — not yet priced
Maxymune Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.